“Obesity (Weight Loss/Weight Management) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Obesity Market.
The Obesity Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Obesity (Weight Loss/Weight Management) Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the emerging therapies for the treatment of Obesity and the aggregate therapies developed by major pharma companies.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Obesity market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Obesity Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Molecule Type
Obesity Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Learn How the Ongoing Clinical & Commercial Activities will Affect the Obesity Therapeutic Segment @
https://www.delveinsight.com/sample-request/obesity-pipeline-insight
Obesity (Weight Loss/Weight Management) Therapeutics Landscape
180 Life Sciences, 9 meters, Aardvark Therapeutics, Adocia, Agentix, AgeX Therapeutics, Altimmune, Amgen, Antag Therapeutics, Aphaia Pharma, Aptorum Group, AstraZeneca, Betagenon AB, BioRestorative, BioRestorative Therapies, Boehringer Ingelheim, Braasch Biotech, Bristol-Myers Squibb, Bukwang Pharmaceutical, Caliway Biopharmaceutics Co Ltd, Can Fite Biopharma, Carmot Therapeutics, Carmot Therapeutics, Inc., Cellivery Therapeutics Inc, CinFina, CinFina Pharma, Clayton Biotech, Click Therapeutics, CohBar, Corbus Pharma, CSPC Baike (Shandong) Biopharmaceutical, D&D Pharmatech, D&D Pharmatech Co Ltd, Daewoong Pharmaceutical, DiscoveryBiomed Inc, Dong-A ST, Dongkook Pharmaceuticals, Eccogene, Elevian, Eli Lilly and Company, Empros Pharma, Enterin Inc., EraCal Therapeutics AG, ERX Pharmaceuticals, Eternygen GmbH, Eurofarma, Gannex Pharma, Glaceum, Gmax Biopharm, GPER G-1 Development Group, LLC, Gubra Therapeutics, Hanmi Pharmaceutical, Hanmi Pharmaceuticals, Innovent Biologics, Jenrin Discovery, Jiangsu Hansoh Pharmaceutical, Kallyope, Kintai Therapeutics, Kriya Therapeutics, LG Life Sciences, Lipidio Pharmaceuticals, MakScientific, Nano Precision Medical, NeonMind Biosciences, Novartis, Novo Nordisk, NuSirt Biopharma, Otsuka Pharmaceutical Factory Inc, Paige Biopharmaceutical (Suzhou) Co., Ltd., Pfizer, Preveceutical Medical Inc, Pylum Biosciences, Raziel Therapeutics, Reata Pharmaceuticals, Regeneron Pharmaceuticals, Reviva Pharmaceuticals, Rivus Pharmaceuticals, RosVivo Therapeutics, Saniona, SciSparc Ltd., Sciwind Biosciences, SCOHIA PHARMA, Shionogi, SHIONOGI & Co., Ltd., Sigrid Therapeutics, SJT Molecular Research SL, Structure Therapeutics, Sun Pharmaceutical Industries, Techfields Pharma, Terns Pharmaceuticals, Tonix Pharmaceuticals, UGISense AG, Versanis Bio, Viking Therapeutics, YSOPIA Bioscience, Yuhan, Zealand Pharma, and many others.
Obesity (Weight Loss/Weight Management) Emerging and Marketed Drugs Covered in the Report Include:
CT-868: Carmot Therapeutics
DD01: D&D Pharmatech
EMP16: Empros Pharma
ERX-1000: ERX Pharmaceuticals
RZL-012: Raziel Therapeutics
Semaglutide oral: Novo Nordisk
Tesomet: Saniona
Tirzepatide: Eli Lilly and Company
ZP 8396: Zealand Pharma
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Obesity Current Treatment Patterns
4. Obesity – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Obesity Late-Stage Products (Phase-III)
7. Obesity Mid-Stage Products (Phase-II)
8. Obesity Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Obesity Discontinued Products
13. Obesity Product Profiles
14. Key Companies in the Obesity Market
15. Key Products in the Obesity Therapeutics Segment
16. Dormant and Discontinued Products
17. Obesity Unmet Needs
18. Obesity Future Perspectives
19. Obesity Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving pharmaceutical market today @ Pharmaceutical Partner Identification Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
